# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-336711
Filing Date
2026-08-06
Accepted
2026-08-06 07:09:25
Documents
80
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | glue-20260630.htm iXBRL | 10-Q | 2639262
2 | EX-31.1 | glue-ex31_1.htm | EX-31.1 | 19241
3 | EX-32.1 | glue-ex32_1.htm | EX-32.1 | 11764
| Complete submission text file | 0001193125-26-336711.txt |  | 10781591

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | glue-20260630.xsd | EX-101.SCH | 1283800
84 | EXTRACTED XBRL INSTANCE DOCUMENT | glue-20260630_htm.xml | XML | 2242090

Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 261245941
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)